Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Bookmark and Share
Published: 2 Jun 2014
Views: 6235
Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

Prof Topp talks to ecancertv at ASCO 2014 about the results of a multicentre phase 2 study of the BiTE antibody blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia. The use of blinatumomab is an antibody treatment which enables chemotherapy to be bypassed in some patients.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.